SAN DIEGO and DUBAI, United Arab Emirates, Jan. 10, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (www.apricusbio.com) (Nasdaq:APRI) and Elis Pharmaceuticals ("Elis") (www.elispharmaceuticals.com), announced today that the two companies have entered into a licensing agreement granting Elis the exclusive rights to market MycoVa™, Apricus Bio's drug for onychomycosis (nail fungal infection), in the Middle East and the Gulf Countries, excluding Israel. The license agreement with Elis follows the recent announcement by the Company of a similar license agreement granting Stellar Pharmaceuticals, Inc. the exclusive right to market MycoVa™ in Canada (http://www.apricusbio.com/press_01032012.html).
